Sun Pharmaceuticals settles drug patent litigation with pharma giants
Date: 2018-01-17   Author: Dhananjay Punekar  Category: #industry

Sun Pharmaceuticals Industries Limited, a key player across the pharmaceuticals industry, has reportedly entered into a pact with Pharma giants Allergan Plc & Ironwood Pharmaceuticals Inc. for resolving the patent dispute over the Linzess drug in the United States.

According to some of the key officials of Sun Pharma, the case related to the drug patent was filed against the firm in response to its abbreviated new drug application under which Sun Pharma is seeking USFDA approval for promoting the generic form of Linzess drug. Medical practitioners have stated that the prescribed medicine is used in treating chronic idiopathic constipation and irritable bowel syndrome in the elderly. As per statistics, the revenue from the sale of the drug had hit USD 506 million in the third quarter of last year, demonstrating a 12% y-o-y growth. It has been reported that in the last quarter of 2017 however, Linzess recorded sales worth USD 191 million, a growth of nearly 16% y-o-y.  As per the market projections, the drug is likely to accrue a revenue of over USD 1 billion as a result of its high demand and favorable purchasing patterns.

As a part of the deal, Ironwood Pharmaceuticals and Allergan Plc will provide a license to Sun Pharmaceuticals to promote Linzess generic across the U.S., effective from 1st February 2031, or even prior to this date, subject to specific conditions. It has been learnt that after the settlement, the patent lawsuit against Sun Pharmaceuticals filed by the two pharma giants will be dismissed. However, as per the key officials of Sun Pharma, the pact is still subject to normal regulatory approvals.

Industry analysts have anticipated that the settlement will have a positive impact on the business growth of Sun Pharma. After the firm’s strategic decision to settle the patent dispute, the firm’s stocks had jumped up from INR 576.40 to INR 578.10 yesterday.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Ensign kicks off a C$947 million bid to take over Trinidad Drilling
Author: Saif Ali Bepari

Ensign Energy Services Inc. is reportedly offering its Calgary-based cross-town neighbor and competitor Trinidad Drilling Ltd. an amount of $1.68 per share. The company aims to commence a hostile C$470-million bid to t...


Contraceptives Market Growth, Business Analysis & Industry Report 2024
Author: Rahul Sankrityayan

Contraceptives Market was valued at USD 21.1 billion in 2016 and is projected to witness 6.8% CAGR growth from 2017 to 2024.

Contraceptive market will witness ...


Cancer Biological Therapy Market Analysis, Trends & Growth Forecast 2024
Author: Rahul Sankrityayan

Cancer Biological Therapy Market size is anticipated to experience significant growth of 6% from 2016 to 2023.

Rising prevalence of cancer patients around the globa...